<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04441008</url>
  </required_header>
  <id_info>
    <org_study_id>202002608</org_study_id>
    <nct_id>NCT04441008</nct_id>
  </id_info>
  <brief_title>Accelerated iTBS for Depression and Suicidality</brief_title>
  <acronym>RAPID</acronym>
  <official_title>Radical aiTBS Protocol for Intractable Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this current study is to evaluate the feasibility, safety, and&#xD;
      tolerability of &quot;high dose&quot; aiTBS in psychiatric inpatient and outpatients with&#xD;
      treatment-refractory unipolar, non-psychotic major depressive disorder, using patients&#xD;
      receiving ECT as an active comparator. Developing a better understanding of the feasibility&#xD;
      and tolerability of adapting this treatment to an acutely ill patient population could lead&#xD;
      to huge breakthroughs for clinician decision-making and for the further optimization of brain&#xD;
      stimulation depression protocols. The results of this study can help guide future&#xD;
      confirmatory efficacy trials of high-dose aiTBS by providing a better understanding of how&#xD;
      feasibility, safety and tolerability compare to ECT, as well as unforeseen challenges of its&#xD;
      use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2023</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-blind with crossover of experimental (aiTBS) group into standard of care (ECT) group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Investigator and outcomes assessor will be blinded to patient's designation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Retention rate at completion of aiTBS vs the ECT group</measure>
    <time_frame>5 days</time_frame>
    <description>The primary tolerability endpoint is the proportion of aiTBS or ECT patients completing the protocol to a degree thought to be satisfactory for achieving the intended antidepressant effect. Completion for aiTBS arm is defined as completion of at least 60% of the treatment protocol (30 of 50 treatments) with treatments on at least 60% of days (3 of 5 days during the week). Completion for ECT arm is defined as completion of at least 2 of 3 ECT treatments during the first week.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Suicide</condition>
  <arm_group>
    <arm_group_label>aiTBS arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aiTBS treatment as lead-in phase to ECT standard of care treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECT arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ECT as clinically indicated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Accelerated Intermittent Theta Burst (aiTBS)</intervention_name>
    <description>High-dose intermittent theta burst administered at a treatment frequency 10x per day, with each treatment session duration 3x standard TMS (1800 pulses). Delivering 50 sessions in 5 days.</description>
    <arm_group_label>aiTBS arm</arm_group_label>
    <other_name>SAINT Protocol, accelerated TMS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electroconvulsive therapy (ECT)</intervention_name>
    <description>ECT as per standard clinical care and management.</description>
    <arm_group_label>ECT arm</arm_group_label>
    <arm_group_label>aiTBS arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Ability to provide informed consent&#xD;
&#xD;
               -  Availability for the duration of the study and willingness to comply with all&#xD;
                  study procedures&#xD;
&#xD;
               -  Age 18 to 90&#xD;
&#xD;
               -  Diagnosis of major depressive disorder by DSM-5 criteria&#xD;
&#xD;
               -  Depressive symptoms are thought to be caused primarily by a major depressive&#xD;
                  episode and not by some other neurologic or psychiatric illness&#xD;
&#xD;
               -  Failure of or intolerance to at least 2 antidepressant treatments of different&#xD;
                  therapeutic classes (can include psychotherapy trial or neurostimulation trial)&#xD;
&#xD;
               -  Meets criteria for clinical eligibility for ECT treatment, including optimization&#xD;
                  of any medical conditions and completion of any medical testing or clearance as&#xD;
                  clinically indicated&#xD;
&#xD;
               -  Able to consent voluntarily to treatment&#xD;
&#xD;
               -  Score of at least 2 on the MADRS item 10&#xD;
&#xD;
               -  Ability to sit or lie down for an extended period of time and willingness to&#xD;
                  adhere to the theta burst stimulation protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Presence of implanted ferromagnetic devices or materials, including cardiac&#xD;
             pacemaker, cochlear implant, deep brain stimulation device, vagus nerve stimulation&#xD;
             device, shrapnel, facial or scalp piercings that cannot be removed, or metallic face&#xD;
             or head tattoos&#xD;
&#xD;
               -  Pregnancy or lactation&#xD;
&#xD;
               -  Previous bad reaction or intolerance to transcranial magnetic stimulation&#xD;
&#xD;
               -  Febrile illness within 1 week&#xD;
&#xD;
               -  Treatment with another investigational drug or other intervention within 30 days&#xD;
&#xD;
               -  Recent substance abuse or use disorder within the past 6 months, excluding&#xD;
                  tobacco or infrequent cannabis use&#xD;
&#xD;
               -  History of epilepsy or seizure disorder&#xD;
&#xD;
               -  History of penetrating traumatic brain injury, multiple sclerosis, or history of&#xD;
                  brain surgery or intracranial hemorrhage&#xD;
&#xD;
               -  Primary psychiatric or medical/neurologic illness other than MDD that is more&#xD;
                  likely to account for depressive symptoms, including severe personality disorder&#xD;
                  or psychotic illness&#xD;
&#xD;
               -  Severe or moderate intellectual disability&#xD;
&#xD;
               -  Major neurocognitive disorder&#xD;
&#xD;
               -  Involuntary commitment or petition filed for involuntary ECT treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Trapp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Pace, MS</last_name>
    <phone>(319) 384-9302</phone>
    <email>benjamin-pace@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicholas Trapp, MD</last_name>
    <phone>(319) 467-8188</phone>
    <email>nicholas-trapp@uiowa.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wirecki TS. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. Brain Stimul. 2016 May-Jun;9(3):336-346. doi: 10.1016/j.brs.2016.03.010. Epub 2016 Mar 16.</citation>
    <PMID>27090022</PMID>
  </reference>
  <reference>
    <citation>Levkovitz Y, Isserles M, Padberg F, Lisanby SH, Bystritsky A, Xia G, Tendler A, Daskalakis ZJ, Winston JL, Dannon P, Hafez HM, Reti IM, Morales OG, Schlaepfer TE, Hollander E, Berman JA, Husain MM, Sofer U, Stein A, Adler S, Deutsch L, Deutsch F, Roth Y, George MS, Zangen A. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry. 2015 Feb;14(1):64-73. doi: 10.1002/wps.20199.</citation>
    <PMID>25655160</PMID>
  </reference>
  <reference>
    <citation>George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE 3rd, Schwartz T, Sackeim HA. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010 May;67(5):507-16. doi: 10.1001/archgenpsychiatry.2010.46.</citation>
    <PMID>20439832</PMID>
  </reference>
  <reference>
    <citation>Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, Knyahnytska Y, Kennedy SH, Lam RW, Daskalakis ZJ, Downar J. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692. doi: 10.1016/S0140-6736(18)30295-2. Epub 2018 Apr 26. Erratum In: Lancet. 2018 Jun 23;391(10139):e24.</citation>
    <PMID>29726344</PMID>
  </reference>
  <reference>
    <citation>Peng Z, Zhou C, Xue S, Bai J, Yu S, Li X, Wang H, Tan Q. Mechanism of Repetitive Transcranial Magnetic Stimulation for Depression. Shanghai Arch Psychiatry. 2018 Apr 25;30(2):84-92. doi: 10.11919/j.issn.1002-0829.217047.</citation>
    <PMID>29736128</PMID>
  </reference>
  <reference>
    <citation>Williams NR, Sudheimer KD, Bentzley BS, Pannu J, Stimpson KH, Duvio D, Cherian K, Hawkins J, Scherrer KH, Vyssoki B, DeSouza D, Raj KS, Keller J, Schatzberg AF. High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. Brain. 2018 Mar 1;141(3):e18. doi: 10.1093/brain/awx379. No abstract available.</citation>
    <PMID>29415152</PMID>
  </reference>
  <reference>
    <citation>Friedrich MJ. Depression Is the Leading Cause of Disability Around the World. JAMA. 2017 Apr 18;317(15):1517. doi: 10.1001/jama.2017.3826. No abstract available.</citation>
    <PMID>28418490</PMID>
  </reference>
  <reference>
    <citation>Zhan Y, Zhang B, Zhou Y, Zheng W, Liu W, Wang C, Li H, Chen L, Yu L, Walter M, Li M, Li MD, Ning Y. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. J Affect Disord. 2019 May 15;251:205-212. doi: 10.1016/j.jad.2019.03.071. Epub 2019 Mar 22. Erratum In: J Affect Disord. 2020 Sep 1;274:1220.</citation>
    <PMID>30927581</PMID>
  </reference>
  <reference>
    <citation>Baeken C. Accelerated rTMS: A Potential Treatment to Alleviate Refractory Depression. Front Psychol. 2018 Oct 31;9:2017. doi: 10.3389/fpsyg.2018.02017. eCollection 2018.</citation>
    <PMID>30429807</PMID>
  </reference>
  <reference>
    <citation>Feffer K, Lee HH, Mansouri F, Giacobbe P, Vila-Rodriguez F, Kennedy SH, Daskalakis ZJ, Blumberger DM, Downar J. Early symptom improvement at 10 sessions as a predictor of rTMS treatment outcome in major depression. Brain Stimul. 2018 Jan-Feb;11(1):181-189. doi: 10.1016/j.brs.2017.10.010. Epub 2017 Oct 19.</citation>
    <PMID>29107623</PMID>
  </reference>
  <reference>
    <citation>Hawley CJ, Gale TM, Sivakumaran T; Hertfordshire Neuroscience Research group. Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord. 2002 Nov;72(2):177-84. doi: 10.1016/s0165-0327(01)00451-7.</citation>
    <PMID>12200208</PMID>
  </reference>
  <reference>
    <citation>Kerner N, Prudic J. Current electroconvulsive therapy practice and research in the geriatric population. Neuropsychiatry (London). 2014 Feb;4(1):33-54. doi: 10.2217/npy.14.3.</citation>
    <PMID>24778709</PMID>
  </reference>
  <reference>
    <citation>Guse B, Falkai P, Wobrock T. Cognitive effects of high-frequency repetitive transcranial magnetic stimulation: a systematic review. J Neural Transm (Vienna). 2010 Jan;117(1):105-22. doi: 10.1007/s00702-009-0333-7. Epub 2009 Oct 27.</citation>
    <PMID>19859782</PMID>
  </reference>
  <reference>
    <citation>George MS, Raman R, Benedek DM, Pelic CG, Grammer GG, Stokes KT, Schmidt M, Spiegel C, Dealmeida N, Beaver KL, Borckardt JJ, Sun X, Jain S, Stein MB. A two-site pilot randomized 3 day trial of high dose left prefrontal repetitive transcranial magnetic stimulation (rTMS) for suicidal inpatients. Brain Stimul. 2014 May-Jun;7(3):421-31. doi: 10.1016/j.brs.2014.03.006. Epub 2014 Mar 19.</citation>
    <PMID>24731434</PMID>
  </reference>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>February 15, 2023</last_update_submitted>
  <last_update_submitted_qc>February 15, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Nicholas Trapp</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>transcranial magnetic stimulation, theta burst, accelerated TMS, ECT, electroconvulsive therapy, depression, suicidality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Suicide</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04441008
org study id: 202002608
nct id: NCT04441008
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: Yes
is us export: No
The overall objective of this current study is to evaluate the feasibility, safety, and
      tolerability of "high dose" aiTBS in psychiatric inpatient and outpatients with
      treatment-refractory unipolar, non-psychotic major depressive disorder, using patients
      receiving ECT as an active comparator. Developing a better understanding of the feasibility
      and tolerability of adapting this treatment to an acutely ill patient population could lead
      to huge breakthroughs for clinician decision-making and for the further optimization of brain
      stimulation depression protocols. The results of this study can help guide future
      confirmatory efficacy trials of high-dose aiTBS by providing a better understanding of how
      feasibility, safety and tolerability compare to ECT, as well as unforeseen challenges of its
      use.
allocation: Randomized
intervention model: Crossover Assignment
intervention model description: Single-blind with crossover of experimental (aiTBS) group into standard of care (ECT) group.
primary purpose: Treatment
masking: Double (Investigator, Outcomes Assessor)
masking description: Investigator and outcomes assessor will be blinded to patient's designation.
measure: Retention rate at completion of aiTBS vs the ECT group
time frame: 5 days
description: The primary tolerability endpoint is the proportion of aiTBS or ECT patients completing the protocol to a degree thought to be satisfactory for achieving the intended antidepressant effect. Completion for aiTBS arm is defined as completion of at least 60% of the treatment protocol (30 of 50 treatments) with treatments on at least 60% of days (3 of 5 days during the week). Completion for ECT arm is defined as completion of at least 2 of 3 ECT treatments during the first week.
arm group label: aiTBS arm
arm group type: Experimental
description: aiTBS treatment as lead-in phase to ECT standard of care treatment.
arm group label: ECT arm
arm group type: Active Comparator
description: ECT as clinically indicated.
intervention type: Device
intervention name: Accelerated Intermittent Theta Burst (aiTBS)
description: High-dose intermittent theta burst administered at a treatment frequency 10x per day, with each treatment session duration 3x standard TMS (1800 pulses). Delivering 50 sessions in 5 days.
arm group label: aiTBS arm
other name: SAINT Protocol, accelerated TMS
intervention type: Device
intervention name: Electroconvulsive therapy (ECT)
description: ECT as per standard clinical care and management.
arm group label: ECT arm
arm group label: aiTBS arm
criteria: 
gender: All
minimum age: 18 Years
maximum age: 90 Years
healthy volunteers: No
last name: Nicholas Trapp, MD
role: Principal Investigator
affiliation: University of Iowa
last name: Benjamin Pace, MS
phone: (319) 384-9302
email: benjamin-pace@uiowa.edu
last name: Nicholas Trapp, MD
phone: (319) 467-8188
email: nicholas-trapp@uiowa.edu
citation: Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wirecki TS. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. Brain Stimul. 2016 May-Jun;9(3):336-346. doi: 10.1016/j.brs.2016.03.010. Epub 2016 Mar 16.
PMID: 27090022
citation: Levkovitz Y, Isserles M, Padberg F, Lisanby SH, Bystritsky A, Xia G, Tendler A, Daskalakis ZJ, Winston JL, Dannon P, Hafez HM, Reti IM, Morales OG, Schlaepfer TE, Hollander E, Berman JA, Husain MM, Sofer U, Stein A, Adler S, Deutsch L, Deutsch F, Roth Y, George MS, Zangen A. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry. 2015 Feb;14(1):64-73. doi: 10.1002/wps.20199.
PMID: 25655160
citation: George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE 3rd, Schwartz T, Sackeim HA. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010 May;67(5):507-16. doi: 10.1001/archgenpsychiatry.2010.46.
PMID: 20439832
citation: Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, Knyahnytska Y, Kennedy SH, Lam RW, Daskalakis ZJ, Downar J. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692. doi: 10.1016/S0140-6736(18)30295-2. Epub 2018 Apr 26. Erratum In: Lancet. 2018 Jun 23;391(10139):e24.
PMID: 29726344
citation: Peng Z, Zhou C, Xue S, Bai J, Yu S, Li X, Wang H, Tan Q. Mechanism of Repetitive Transcranial Magnetic Stimulation for Depression. Shanghai Arch Psychiatry. 2018 Apr 25;30(2):84-92. doi: 10.11919/j.issn.1002-0829.217047.
PMID: 29736128
citation: Williams NR, Sudheimer KD, Bentzley BS, Pannu J, Stimpson KH, Duvio D, Cherian K, Hawkins J, Scherrer KH, Vyssoki B, DeSouza D, Raj KS, Keller J, Schatzberg AF. High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. Brain. 2018 Mar 1;141(3):e18. doi: 10.1093/brain/awx379. No abstract available.
PMID: 29415152
citation: Friedrich MJ. Depression Is the Leading Cause of Disability Around the World. JAMA. 2017 Apr 18;317(15):1517. doi: 10.1001/jama.2017.3826. No abstract available.
PMID: 28418490
citation: Zhan Y, Zhang B, Zhou Y, Zheng W, Liu W, Wang C, Li H, Chen L, Yu L, Walter M, Li M, Li MD, Ning Y. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. J Affect Disord. 2019 May 15;251:205-212. doi: 10.1016/j.jad.2019.03.071. Epub 2019 Mar 22. Erratum In: J Affect Disord. 2020 Sep 1;274:1220.
PMID: 30927581
citation: Baeken C. Accelerated rTMS: A Potential Treatment to Alleviate Refractory Depression. Front Psychol. 2018 Oct 31;9:2017. doi: 10.3389/fpsyg.2018.02017. eCollection 2018.
PMID: 30429807
citation: Feffer K, Lee HH, Mansouri F, Giacobbe P, Vila-Rodriguez F, Kennedy SH, Daskalakis ZJ, Blumberger DM, Downar J. Early symptom improvement at 10 sessions as a predictor of rTMS treatment outcome in major depression. Brain Stimul. 2018 Jan-Feb;11(1):181-189. doi: 10.1016/j.brs.2017.10.010. Epub 2017 Oct 19.
PMID: 29107623
citation: Hawley CJ, Gale TM, Sivakumaran T; Hertfordshire Neuroscience Research group. Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord. 2002 Nov;72(2):177-84. doi: 10.1016/s0165-0327(01)00451-7.
PMID: 12200208
citation: Kerner N, Prudic J. Current electroconvulsive therapy practice and research in the geriatric population. Neuropsychiatry (London). 2014 Feb;4(1):33-54. doi: 10.2217/npy.14.3.
PMID: 24778709
citation: Guse B, Falkai P, Wobrock T. Cognitive effects of high-frequency repetitive transcranial magnetic stimulation: a systematic review. J Neural Transm (Vienna). 2010 Jan;117(1):105-22. doi: 10.1007/s00702-009-0333-7. Epub 2009 Oct 27.
PMID: 19859782
citation: George MS, Raman R, Benedek DM, Pelic CG, Grammer GG, Stokes KT, Schmidt M, Spiegel C, Dealmeida N, Beaver KL, Borckardt JJ, Sun X, Jain S, Stein MB. A two-site pilot randomized 3 day trial of high dose left prefrontal repetitive transcranial magnetic stimulation (rTMS) for suicidal inpatients. Brain Stimul. 2014 May-Jun;7(3):421-31. doi: 10.1016/j.brs.2014.03.006. Epub 2014 Mar 19.
PMID: 24731434
responsible party type: Principal Investigator
investigator affiliation: University of Iowa
investigator full name: Nicholas Trapp
investigator title: Assistant Professor of Psychiatry
mesh term: Depression
mesh term: Depressive Disorder
mesh term: Depressive Disorder, Major
mesh term: Suicide
sharing ipd: No